AUTHOR INDEX

Volume 23, 1992

Aaronson, N., 223
Abe, M., 759
Abe, Y., 847
Abner, A. L., 925, 949
Adler, J., 413
Agbi, C. B., 321
Ahn, D. K., 3, 853
Akoush, H. H., 511
Akuta, K., 759
Al-Sarraf, M., 705
Aletti, P., 715
Allalunis-Turner, M. J., 339
Allen, P. K., 407
Amdur, R. J., 769
Anderson, B., 501
Anderson, M. W., 449
Andrews, J. C., 781
Ang, K. K., 639
Anikin, V. A., 873
Anscher, M. S., 1095
Appelbaum, F. R., 1027
Aristei, C., 401
Armstong, J. G., 605
Asbell, S. O., 293
Ash, R. C., 681
Ashley, S. E., 313
Ashtari, M., 255
Asselain, B., 483
Astrahan, M. A., 599
Auger, E. A., 891
Aversa, F., 401
Awwad, H. K., 511
Aygun, C., 127, 251

Babaian, R. J., 1095
Bader, J. L., 915
Bagshaw, M. A., 413
Balter, J. M., 153
Baltschukat, K., 345
Barber-Derus, S. W., 681
Barbot, D., 305
Barnett, T. A., 585
Barron, G. M., 339
Bates, T., 215, 217
Baumann, M., 803
Beach, J. L., 255
Bébéar, J. P., 147
Beck, E. R., 539
Beck-Bornholdt, H.-P., 678
Ben-Baruch, N., 915
Bensinger, W. F., 1027
Bernstein, M., 321
Bessell, E. M., 313
Bey, P., 715
Biermann, W., 305
Binns, W. R., 1059
Birnbaum, S., 27
Bjarngard, B., 1079
Blaszka, B., 483
Blitzer, P., 215, 621
Bloom, H. J. G., 313
Bondy, M. L., 407
Bongiorni, P., 175
Bonner, H., 9
Borgen, P. I., 969
Botet, J., 165
Bova, F. J., 769
Brada, M., 313
Bradley, E. W., 821
Brenner, D. J., 252
Bridges, J. M., 551
Brown, I., 563
Brown, J. M., 891
Brown, M. B., 781
Brugère, J., 483
Brunin, F., 483, 677
Buatti, J. M., 533
Buckner, C. D., 1027
Budach, V., 69
Buskirk, S. J., 141

Cabanillas, F., 407
Campbell, B. H., 705
Cancer and Leukemia Group B, 1021
Cant, J., 433
Cantell, K., 863
Cantor, R., 305
Carl, U., 361
Carotti, A., 401
Carpenter Jr., R. J., 407
Carpenter, R. N., 563
Carter, D., 175
Cassady, J. R., 533
Cassisi, N. J., 725
Castro, J. R., 881
Caudry, M., 147
Chaccaglini, F., 401
Chan, D. K. K., 261
Chandan-Langlie, M., 115
Chao, C., 1045
Chaplin, D. J., 573
Chen, G. T. Y., 153, 367
Chen, M. G., 519
Cheung, F. K., 261
Chosy, L., 133
Clegg, S. T., 1009
Clift, R. A., 1027
Cobb, E. D., 1009
Cohen, A. M., 387
Cohen, E. P., 681
Coia, L. R., 201, 223, 229, 239
Colby, T. V., 519
Coleman, E. N., 1009
Colkitt, D., 1094
Collier, J. M., 881
Committe of Radiation Oncology Group Chairmen, 1079
Connors, S., 1051
Convery, K., 27
Cooper, J. S., 207, 671
Cooper, S. G., 433
Cosmatos, D., 207
Cosset, J. M., 677
Costello, S. A., 477
Coster, J. R., 743
Coughlin, C. T., 189, 207
Cowan, K. H., 915, 1093
Cox, J. D., 1037
Cox, R. S., 413
Crommelin, M. A., 299
Crook, J., 479
Cross, P., 433
Cundiff, J. H., 397, 407

Daftari, I., 881
Dahl, O., 109
Danforth, D., 915
Darrouzet, V., 147
Davis, L., 1045
Davis, M., 397
Davis, R. L., 3
Day III, R. S., 339
de la Rochefordiere, A., 925
De Neve, W., 299
DeCaro, L., 397
Deeg, H. J., 1027
Dehner, L. P., 615
Delclos, L., 491
Denham, J. W., 433
Denison, L., 579
Deore, S. M., 281
Derdel, J. D., 1094
DeSanto, L. W., 743
Deutsch, M., 1083
Devineni, V. R., 271
Dewhirst, M. W., 377, 1009
Diamond, A. M., 999
Dinshaw, K. A., 281
Dische, S., 678
Dodge, R. K., 377
Doggett, R. L. S., 293
Donaldson, S. S., 253
Doney, K., 1027
Doornbos, J. F., 501
Dubben, H.-H., 678
DuBois, W., 55, 803
Duncan, G., 239
Dunst, J., 907
DuRoss, D. J., 781

Earle, J. D., 1094
Eifel, P. J., 491
El Attar, I., 511
El-Khatib, E., 1051
Ellerbroek, N., 397
Ellis, D. S., 253
Ellis, J. H., 169
Emami, B. N., 615
Enker, W. E., 387
Ensminger, W. D., 781
Epstein, A. H., 19
Ervin, T. J., 705
Esche, B., 479
Ewald, L. M., 769

Fagundes, H. M., 615
Faid, A., 477
Feehan, P. E., 881
Feldmann, H. J., 1003
Ferrigni, R. G., 141
Fineberg, B., 285
Fleming, T. J., 639
Flickinger, J. C., 19
Floquet, A., 147
Foo, W., 261
Foote, R. L., 743
Forçard, J.-J., 715
Fowble, B. L., 933, 941, 961
Fowler, J. F., 133, 457, 661, 811, 1098
Fox, S., 869
Freeman, D. E., 733, 889
Freeman, J., 803
Frick, L. M., 141
Fu, K., 881
Fujii, T., 751
Fuller, B. G., 413
Fuller, G. L., 1059
Fuller, L. M., 407
Fullerton, B., 27
Fulton, D. S., 339

Gahbauer, R. A., 705
Galvin, J. M., 621, 789
Garcia, D. M., 285, 615
Gatzemeier, W., 907
Gauthier, F., 525
Gauwitz, M., 397
Gehan, E. A., 1095
Genest, P., 479
Gerdes, H., 165
Gerweck, L. E., 55, 557
Giaccia, A. J., 891
Gillette, E. L., 539, 1093
Gillin, M. T., 627
Gioioso, D., 55
Glatstein, E., 247, 1093
Glicksman, A. S., 1079
Goffman, T. E., 247
Goitein, M., 27, 99
Goldstein, J., 1045
Goldwein, J. W., 621, 627
Goodman, G. B., 573
Goodman, R. L., 789, 961
Goor, C., 299
Gould, D. H., 539, 1093
Gray, M. J., 477
Grdina, D. J., 999
Green, R., 599
Greenberger, J. S., 675
Grigsby, P. W., 673, 869
Grimard, L., 479
Grimes, M., 737
Grulkey, W., 573
Gruner, M., 525
Guérin, J., 147
Gutin, P. H., 3, 853

Habrand, J.-L., 525, 677
Hackl, A., 183

Hagemeister, F. B., 407
Hahn, G. M., 891
Hahn, P., 419
Haissig, S., 115
Hall, E. J., 252
Halme, M., 863
Halperin, E. C., 1021
Halpern, H. J., 153, 367
Halverson, K. J., 285
Ham, B., 853
Hamamoto, K., 751
Hanks, G. E., 201, 203, 293
Hansen, J. A., 1027
Hanson, W. R., 333
Haraf, D. J., 999
Harari, P. M., 533
Harmon, M., 133
Harris, J. R., 925, 949
Harrison, L. B., 605
Haselow, R. E., 705
Hauer, C., 183
Herzog, A., 949
Hilaris, B. S., 1033
Hiraoka, M., 759
Ho, J. H. C., 261
Hodgkiss, R. J., 361
Hoederath, A., 1003
Hoffstetter, S., 715
Holly, F. E., 977
Holsti, L. R., 863
Hong, W. K., 885
Hornback, N., 207
Hortobagyi, G. N., 1085
Huang, D. T., 737, 1096
Hughes, L. L., 983
Huntzinger, C. J., 789
Hussey, D. H., 501

Idicula, J., 393
Iliakis, G., 353
Inoue, K., 751
Ishine, M., 751
Itoh, H., 751
Ivanov, V. N., 873
Ivanova, L. F., 873

Jack, S. M., 743
Jacobs, J. R., 705
Jani, S. K., 501
Janjan, N. A., 647
Jaulerry, C., 483, 677
Jo, S., 759
Johnson, C. R., 737
Joiner, M. C., 361
Jose, C. C., 393
Joseph, D. J., 433
Jouve, M., 483

Kaanders, J. H. A. M., 639
Kalbaugh, K. J., 769
Kalifa, C., 525, 677
Kaplan, I. D., 413
Kapp, D. S., 585
Kataoka, M., 751
Kaulfersch, W., 183
Kawamura, M., 751
Keisch, M., 869
Kelley, M., 175
Kerman, H. D., 9
Kessler, M. L., 781
Kim, Y., 811
King, C. R., 175
Kinsella, T. J., 133, 811
Kittelson, J. M., 533
Kivisaari, L., 863
Kjellen, E., 361
Klaes, W., 69
Klarmann, J., 1059
Kligerman, M. M., 789
Komaki, R., 397, 1037
Kondziolka, D., 19
Koong, A., 891
Koprowski, C., 254
Koutcher, J. A., 557
Kowalyshyn, M. J., 961
Krall, J. M., 293
Kraybill, W. G., 615
Kris, M. G., 605
Krümpelmann, S., 1003
Kucik, N. A., 271, 615
Kuske, R. R., 207, 285
Kynaston, B., 327

Lai, P. P., 615, 1095
Lam, G. K. Y., 573
Lamb, S. A., 853
Lamborn, K., 3, 853, 853
Langholz, B., 599
Langmann, A., 183
Laperriere, N., 321
Lappin, T. R. J., 551
Laramore, G. E., 705
Larson, D. A., 3, 853
Latini, P., 401
Laurie, F., 1079
Lavey, R., 41, 1097
La Vigne, M. L., 169, 781
Law, S. C. K., 261
Lawrence, G. A., 1094
Lawrence, T. S., 781
Lawton, C. A., 681
Lawton, P. A., 239
LeCouter, R. A., 539
Lee, A. W. M., 261, 678
Lee, C. G., 969
Lemerle, J., 525
Leung, P., 321
Levitt, S. H., 903
Lichter, A. S., 781
Liggett, P., 599
Lightdale, C., 165
Lin, P.-S., 1096
Lindstrom, M. J., 457, 811
Ling, C. C., 81
Linggood, R., 223
Lingos, T. I., 949
Lippman, M., 915, 1093
Loeffler, J., 223
Logus, W., 1051
Luengas, J., 983
Lumley, M., 321
Lunsford, L. D., 19
Luporsi, E., 715
Luxton, G., 599
Lybeert, M. L. M., 299
Lyman, J. T., 781
Maasilta, P., 863
MacManus, M. P., 551
Maher, E. J., 201, 239
Maher, J., 215
Maire, J. P., 147
Maitz, A. H., 19
Malissard, L., 715
Malkinson, F. D., 333
Maor, M. H., 639
Maranzano, E., 401
Marcial-Vega, V., 271
Marcus, K. C., 443
Marks, J. E., 271
Marks, L. B., 1021
Martelli, M. F., 401
Martin, R. F., 579
Martini, N., 605
Martz, K. L., 9
Maruyama, Y., 252, 255
Marx, D., 907
Mastoras, C. A., 1033
Masunaga, S.-I., 759
Mattson, K., 863
Mauch, P. M., 443
Mazumdar, M., 969
McAleer, J. J. A., 551
McBride, W. H., 977
McCormick, B., 969
McDougall, I. R., 253
McKeown, S. R., 551
McLaughlin, P., 407
Medvedev, V. S., 873
Meechan, P. J., 999
Mehta, M. P., 133, 251
Mella, O., 109
Mendenhall, W. M., 41, 725, 733, 769, 889, 1097
Meritz, K., 1045
Michael, B., 789
Million, R. R., 691, 725, 733, 769, 889
Min, W. S., 115
Minchinton, A. I., 891
Minehan, K. J., 519
Minsky, B. D., 165, 387
Mitchell, J. B., 115
Mitchell, J. S., 563
Moeller, R. D., 789
Mohiuddin, M., 305
Molls, M., 1003
Monthofer, S. P., 1059
Moorthy, C. R., 1033
Morgan, W. F., 993
Morris, M., 491
Morrow, M., 1071
Mosseri, V., 483
Moulder, J. E., 681
Mount, M., 661
Murray, D., 983
Murray, K. J., 9, 681
Myrianthopoulos, L. C., 153, 367

Nagata, Y., 759
Nath, R., 175
Needham, M., 789
Nehme, D., 525
Nelson, A. K., 333
Nelson, D. F., 9
Nelson, J. S., 9
Nelson, O. S., 215
Newall, J., 9
Niemierko, A., 89, 99
Nishimura, Y., 759
Nothdurft, W., 345

Obuz, V., 115
Oleson, J. R., 377
Olsen, K. D., 743
Omar, S., 511
O'Shaughnessy, J., 915
Oswald, M. J., 491, 1037

Page, R. L., 377
Pahule, A., 647
Pais, A., 393
Pakisch, B., 183
Palta, J., 429
Panizza, B. M., 401
Pardo, F., 55
Parsons, J. T., 41, 725, 733, 769, 889
Patel, P., 252
Pelizzari, C. A., 153, 367
Pelka, A. E., 333
Perera, H., 1059
Perez, C. A., 271, 285, 293, 615, 869, 1095
Pernot, M., 715
Perrucci, E., 401
Peschel, R. E., 254
Petereit, D., 133
Peters, L. J., 245, 639, 887
Peters, W., 1021
Petersen, I. A., 253
Peterson, F. B., 1027
Petrovich, Z., 599
Petti, P., 881
Phillips, T. L., 3, 853, 881
Pierce, L., 915, 1093
Pierce, S. M., 949
Pilepich, M. V., 293
Poier, E., 183
Point, D., 483
Pollack, A., 1037
Pontvert, D., 483
Poon, Y. F., 261
Porrazzo, M. S., 1033
Pouillart, P., 483
Poulsen, M. G., 327
Poulter, C. A., 207
Powers, B. E., 539, 1093
Powlis, W. D., 789
Prados, M. D., 3, 853
Pratt, G. R., 327
Prescott, D. M., 377
Priestman, T. J., 223
Prosnitz, L. R., 1021, 1095
Pu, A., 803
Putnam Jr., J. B., 397, 1037

Ramadas, K., 393
Rangad, F., 393
Rauschecker, H. F., 907
Raveendran, P., 393
Recht, A., 925, 949
Reisinger, S. A., 429
Rhodes, L. P., 443
Ribot, J. G., 299

Rich, T. A., 983
Rine, G. P., 1009
Ritter, M. A., 811
Ro, J. Y., 1037
Roberts, J. A., 169
Robertson, J. M., 781
Robinow, J. S., 141
Rockwell, S., 175
Rodriguez, J., 483
Rodriguez, M. A., 407
Rofstad, E. K., 63
Rogers, C. C., 821
Rogoff, E. E., 533
Rojas, A., 361
Rosato, F., 305
Rosenthal, S. A., 621
Rosner, G. L., 1021
Ross, M., 1021
Rotman, M., 207
Roul, R. K., 393
Rubenstein, J., 789
Rubin, J., 1045
Rubin, P., 1, 207, 215, 259, 293, 481, 690, 901
Russell, A. H., 449
Ryan, M. B., 397
Ryan, T. P., 189

Sack, H., 69, 1003
Salvaras, N., 1033
Samulski, T. V., 377, 1009
Sanders, J. E., 1027
Sarrazin, D., 525
Satoh, M., 751
Sauer, R., 907
Saunders, M. I., 678
Sause, W. T., 293
Scariato, A., 127, 251
Schaid, D. J., 743
Schea, R. A., 169
Schem, B.-C., 109
Schild, S. E., 141
Schmidt-Ullrich, R., 737, 1096
Schmoor, C., 907
Schoeppel, S. L., 169
Schroy, C. B., 255
Schultheiss, T. E., 1089
Schuller, D. E., 705
Schultz, D. J., 933, 941, 961
Schumacher, M., 907
Schuricht, A., 305
Schwade, J. G., 705
Scott, C. B., 705
Seegenschmiedt, M. H., 907
Selig, C., 345
Seneviratne, T., 557
Shahabi, S., 133
Shalev, S., 419
Shank, B., 1087
Sharma, V., 281
Shaw, E. G., 519
Shih, L. L., 1033
Shimm, D. S., 533
Shin, D. M., 1037
Sigurdson, E., 387
Silver, B., 925, 949
Silver, C., 1045
Simons, S. R., 19
Simpson, J. R., 271, 285, 615
Skates, S., 27
Smit, B. J., 477
Smith, A. R., 621, 789
Smith, T. L., 491
Sneed, P. K., 3, 853
Soliman, O., 511
Solin, L. J., 473, 789, 933, 941, 961
Song, C. W., 115
Spearman, D., 127, 251
Speiser, B. L., 249
Spelbring, D. R., 153, 367
Srinivasan, V., 841
Stabile, L., 1033
Staples, J. J., 501
Stark, L., 127, 251
Stauffer, P. R., 853
Stephens, L. C., 1089
Stewart, M., 419
Storb, R., 1027
Stringer, S. P., 725
Stücklschweiger, G., 183
Stuschke, M., 69
Su, J. Q., 519
Subhashini, J., 393
Suen, S., 853
Suit, H. D., 27, 55, 653, 803
Sullivan, K. M., 1027
Supe, S. J., 281
Svensson, G., 443
Swain, S., 915
Swan Jr., F., 407

Taghian, A., 55, 715
Taifu, L., 469
Takahashi, M., 759
Takai, Y., 573
Takashima, S., 751
Tatsuzaki, H., 27
Taylor, J. H., 189
Taylor, J. M. G., 41, 1097
Tchelebi, A. E., 1033
Ten Haken, R. K., 781
Terrier-Lacombe, M.-J., 525
Terris, D. J., 891
Thaw, M., 261
Thomadsen, B., 133
Thoms Jr., W. W., 491
Thomson, J. W., 9
Thrall, D. E., 377
Ting, J., 1045
Tomera, K. M., 141
Tomkinson, K., 55
Tripcony, L. B., 327
Tung, S. Y., 261
Tupchong, L., 429
Turner, D. A., 501

Uckun, F. M., 115
Urano, M., 252, 593, 847
Urban, C., 183
Urie, M. M., 27, 99
Urtasun, R. C., 207, 339

Valcarcel, E. R., 993
Validire, P., 483
Vanuytsel, L. J., 313
Varghese, C., 393
Vegesna, V., 977
Velasquez, W. S., 407
Venzon, D., 915
Vetto, J., 969
Vicini, F., 925, 949
Viggars, D. A., 419
Vigliotti, A. P., 501
Vijayakumar, S., 153, 367
Vikram, B., 1097
Vredenburgh, J. J., 1021
Vtyurin, B. M., 873
Wallen, C. A., 831, 1009
Wallner, K. E., 254
Walter, J. P., 449
Wang, Y., 353
Wara, W. M., 3, 853
Wasserman, T. H., 1079
Weaver, K. A., 853
Weigensberg, I., 207
Weiner, S., 127, 251
Weiss, J. F., 841
Weiss, M. C., 933, 941, 961
Weissman, D. E., 647
Wen, B.-C., 501
Wharton, J. T., 491
Wheeler, K. T., 831
Wheeler, R., 705
Wierzbicki, J., 255
Wilder, R. B., 533
Williamson, J. F., 1059
Wilson, C. B., 3
Wilson, G. D., 361
Wilson, J. F., 627
Withers, H. R., 977
Witherspoon, R. P., 1027
Wong, J. W., 1059
Wong, K.-H., 593, 831
Woo, S. Y., 407
Wu, A., 19
Wynne, C. J., 477

Yaes, R. J., 252, 255
Yanch, J., 255
Yarnold, J. R., 215
Yates, B. L., 993
Yeh, I-T., 961
Yeh, L'T., 941
Yokoyama, S., 751

Zafrani, B., 483
Zagars, G. K., 47
Zaghloul, M. S., 511
Zaidi, S. T. H., 557
Zamenhof, R., 255
Zellmer, D. L., 627
Zhang, H., 831
Zimmerman, D., 519
Zook, B. C., 821
Zukowski, C. L., 449

SUBJECT INDEX

Volume 23, 1992

A

Access to care, 203
Acquired immunodeficiency syndrome (AIDS), 1045
Actinomycin D, 977
Adjuvant radiotherapy, 907
Adriamycin, 977
Advanced cancer, 239
Alkaline phosphatase isoenzyme, 563
Alkylating agents, 593
Alopecia, 333
α-autoradiography, 563
Alpha/beta ratio, 573
Alpha-interferon, 863
α-tocopherol, 841
Altered fractionation regimen in cranial irradiation, 229
Analysis
  Data, 633
  Dose-volume histogram, 781
Anaplastic astrocytoma, 3
Antennas
  Dipole, 189
  Helical, 189
Arteriovenous, 19
Assay(s)
  Colony forming, 69
  Gel retardation, 891
  Predictive, 339
Atypical hyperplasia, 1071
Au-198, 81

B

BCNU, 831
Beam's eye view, 153, 367
Benign breast disease, 1071
Beta radiation, 533
Bile duct tumors, 165
Bilharziasis, 511
Biophysical models, 99
Bladder
  Carcinoma, 511
  T2 cancer, 299
Blood flow, 1009
  Tumor, 1003
Bone
  Marrow transplant, 1021
  Metastases, 207, 217
Borderline breast lesions, 1071
Brachial plexopathy, 949
Brachytherapy, 133, 165, 175, 627, 661, 715, 1033, 1059
  Endobronchial, 127
  High dose rate, 127
  Interstitial, 3, 321, 853
  Perioperative, 873
Brain
  Metastasis(es), 223, 229, 413
  Neoplasm, 853
  Primary non-Hodgkin's lymphoma, 9
  Reticulum cell carcinoma, 9
  Tumor model, 109
Breast
  Benign disease, 1071
  Borderline lesions, 1071
  Cancer, 285, 907, 915, 925, 933, 949, 1021
  Cancer risk, 1071
  Carcinoma, 941, 961
  Conservation treatment, 961
  Infiltrating cancer, 969
  Irradiation, 433
  Recurrence, 941
Bromodeoxyuridine, 811
B-16 melanoma, 573
Bulky endocervical cancer, 491

C

Cancer, 189
  Advanced, 239
  Breast, 285, 907, 915, 925, 933, 949, 1021
  Bulky endocervical, 491
  Cervical, 449, 501
  Head and neck, 483, 639, 647, 705
  Infiltrating breast, 969
  Locally advanced colorectal, 759
  Lung, 127, 133
  Non-small cell lung, 863
  N2 lung, 605
  Pain, 647
  Pancreatic, 305
  Prostate, 141, 293
  Rectal, 387
  Recurrent lung, 397
  T2 bladder, 299
  Vocal cord, 281
Canine, 539
Carboplatin, 109
Carcinoma(s)
  Bladder, 511
  Breast, 941, 961
  Cervix, 393
  Colloid, 941
  Ductal *in situ*, 941
  Hepatocellular, 525
  Infiltrating ductal, 941
  Infiltrating lobular, 941
  Medullary, 941
  Nasopharyngeal, 261, 881
  Pancreatic, 751
  Reticulum brain cell, 9
  Squamous cell, 803
  Tubular, 941
Cell(s)
  Clonogenic, 115
  Cycle, 345
  Granulocyte/macrophage progenitor, 345
  Human colon adenocarcinoma, 983
  Kinetics, 811
  Stem, 69
  Survival, 993
Central nervous system neoplasms, 429
Cervical
  Cancer, 449, 501
  Neoplasm, 165
Cervix carcinoma, 393
Cf-252, 873
Charged particle radiotherapy, 881
Chemosensitization, 593, 831
Chemotherapy, 3, 305, 519, 705, 949
  High dose, 1021
  Induction, 483, 605
Children, 525
Choroidal melanoma, 599
Chromosomal aberrations, 993
Cisplatin, 109
Clinical trial design, 293
Clonogenic cell, 115
CNS
  Lymphoma, 9
  Tolerance, 27
Colloid carcinoma, 941
Colony forming assay, 69
Combined modality
  Therapy, 781
  Treatment, 705
Combined treatment, 491
Complication(s), 27, 491, 585, 639, 715, 949
  Cranial irradiation, 229
  Late, 281
  Radiation, 19
  Wound, 41
Computer(s), 869
  Graphics, 367
  Personal, 633
Computerized chart, 633
Consensus management, 239
Consequential late effect, 847
Conservative
  Surgery, 925, 949
  Surgery and radiation, 933
Control
  Local, 653
  Local-regional, 915
Conventional fractionation, 511
Cosmesis, 925
Cost of care, 203
Cranial irradiation, 183
  Altered fractionation regimen, 229
  Complications, 229
Cranial nerves, 27
C3H mouse, 847

D

Data analysis, 633
Density correction, 419
Diabetes insipidus, 519
Dipole antennas, 189
Disease
  Benign breast, 1071
  Hodgkin's, 407, 443
Disease- free survival, 653
Distant metastasis, 653
DNA
  Double-strand breakage, 993
  Double-strand breaks, 353, 983
  Ligands, 579
  Plasmid, 579
  Repair, 983
  Strand breaks, 579
Dog, 821
Dose
  Effect factor, 977
  Fetal, 407
  Per fraction, 281
  Prescription, 419

Response, 27
Scatter, 433
Time effects, 41
To eye and lens, 183
Dose-rate
High, 133
Low, 661
Dose-volume
Effects, 175
Histogram analysis, 781
Histograms, 419
Dosimetry, 169, 627, 1059
Lung and bone, 1051
Radiation, 433
Doubling time, 457
Ductal carcinoma *in situ*, 941
Dynamic CT, 1003

E

Education, 869
Effect(s)
Consequential late, 847
Dose time, 41
Dose-volume, 175
Late radiation, 847
Electron(s) 769
Beam, 751
Endobronchial, 397
Brachytherapy, 127
Radiation, 133
Endoradiotherapy, 563
Energy status, 557
Epilation, 977
ERD values, 281
Extended field irradiation, 501
Extracapsular extension, 737
Eye, 769

F

Factor(s)
Dose effect, 977
Heat shock transcription, 891
Prognostic, 271, 907
Failure-free rates, 261
Fast neutrons, 821
Fetal dose, 407
Fibrosis, 847
Films
Portal, 621
Verification, 621
5-fluorouracil, 983
5'-iododeoxyuridine, 353
Flow cytometry, 811
Foot reaction, 847
Fraction
Hypoxic, 361
Hypoxic cell, 557
Fractionated
Radiation therapy, 147
Radiotherapy, 803
Fractionation, 361, 457, 847
Conventional, 511

G

Gamma knife, 19
Gamma-radiation, 983
Gel retardation assay, 891
Glioma(s), 339, 853
Malignant, 3, 55, 803
Glutathione, 339
Granulocyte/macrophage progenitor cells (GM-CFC), 345
Growth delay, 803
Gynecologic implant, 169

H

Halogenated pyrimidine radiosensitization, 353
H-atom donation, 579
Head and neck
Cancer, 483, 639, 647, 705
Neoplasms, 621, 733
Heat shock transcription factor, 891
Helical antennas, 189
Helium ion radiotherapy, 881
Hemibody irradiation, 207
Hepatoblastoma, 525
Hepatocellular carcinoma, 525
High dose chemotherapy, 1021
High dose rate, 133
Brachytherapy, 127
High LET (linear energy transfer) radiation, 573
Histiocytosis
Langerhans cell, 519
X, 519
Histopathology, 539
HLA-matched bone-marrow transplants, 401
Hodgkin's disease, 407, 443
Hoechst
33258, 579
33342, 549
Human
Colon adenocarcinoma cells, 983
Tumor xenografts, 803
Tumors, 811
Hyperfractionated total body irradiation, 401
Hyperfractionation, 393
Hyperthermia, 109, 115, 189, 377, 585, 593, 599, 853, 1009
Regional, 759, 1003
Hypobaric hypoxia, 551
Hypotensive agents, 377
Hypoxia, 831, 891
Hypobaric, 551
Hypoxic
Cell fraction, 557
Fraction, 361
Metabolism, 593

I

Implant(s)
Gynecologic, 169
Interstitial, 299
Permanent, 81
In situ ductal carcinoma, 941
In vitro SF2, 63
Induction chemotherapy, 483, 605
Infiltrating
Breast cancer, 969
Ductal carcinoma, 941
Lobular carcinoma, 941
Intermittent, 661
Interstitial, 189
Brachytherapy, 3, 321, 853
Implant, 299
Pneumonitis, 401
Intracavitary, 189
Intracranial ependymoma, 313
Intraluminal radiotherapy, 397
Intraoperative radiation therapy, 751
Intraoral stents, 639
Intrinsic radiosensitivity, 55
Iodine-125, 81, 305, 321
Irradiation, 539
Altered fractionation regimen in cranial, 229
Breast, 433
Complications of cranial, 229
Cranial, 183
Extended field, 501
Hemibody, 207
Hyperfractionated total body, 401
Mantle, 443
Neutron, 873
Periaortic lymph node, 501
Postoperative, 511
Stereotactic external beam, 229
Total body, 1051

K

Kidney(s), 361, 821

L

Langerhans cell histiocytosis, 519
Laryngeal neoplasms, 725
Late
Complications, 281
Radiation effect, 847
Lesions
Borderline breast, 1071
Localized, 751
Leukemia, 115
Linear-quadratic model, 661
Liver tumors, 781
Local
Anesthetics, 585
Control, 653
Local-regional
Control, 915
Recurrence, 285
Localized lesions, 751
Locally advanced, 915
Colorectal cancer, 759
Long-term survival results, 261
Low
Dose-rate, 661
Energy radionuclide, 1033
Lumpectomy, 941
Lung and bone dosimetry, 1051
Lung cancer, 127, 133
Non-small cell, 863
N2, 605
Recurrent, 397
Lymph node evaluation, 293
Lymphoma
CNS, 9
Primay non-Hodgkin's brain, 9

M

Magnetic resonance (MR)
Imaging, 449
Studies, 169
Malformation, 19
Malignant
Astrocytoma, 321
Fibrous histiocytoma, 615
Glioma, 3, 55, 803
Parotid tumors, 327

Mantle irradiation, 443
Mastectomy, 907, 969
Mediastinal adenopathy, 443
Medicine, 869
Medullary carcinoma, 941
Melanoma
  B-16, 573
  Choroidal, 599
  Xenografts, 63
Mer phenotype, 339
Metastasis(es)
  Bone, 207, 217
  Brain, 223, 229, 413
  Distant, 653
Mice, 333
Microdosimetry, 627
Microglioma, 9
Microinvasion, 961
Microwave, 189, 853
  Applicator, 1009
Misonidazole, 593, 831
Model(s)
  Biophysical, 99
  Brain tumor, 109
  Linear-quadratic, 661
Modeling, 89
  Two-dimensional, 1009
Monte Carlo simulation, 1059
Multicellular spheroids, 69
Multidrug resistance, 115
Multiple
  Fraction per day, 511
  Fractions, 661

N

Nasopharyngeal carcinoma, 261, 881
Nasopharynx, 271
Neck
  Dissection, 41, 743
  Nodes, 733
Neon ion radiotherapy, 881
Neoplasm(s)
  Brain, 853
  Central nervous system, 429
  Cervical, 169
  Head and neck, 621, 733
  Laryngeal, 725
  Skin, 769
Neurinomas, 147
Neutron(s)
  Fast, 821
  Irradiation, 873
Nitromin, 551
Nitroprusside, 377
Non-small cell lung cancer, 863
Normal tissue
  Complication probability, 781
  Reactions, 393
  Tolerance, 27
Normalization, 419
Normobaric
  Carbogen, 361
  Oxygen, 361
N2 lung cancer, 605

O

Oncology, 869
  Radiation, 633
Optic nerve tolerance, 27
Optimization, 89, 99
  Treatment plan, 153, 367
Organ preservation, 387
Oropharynx, 715
Outcome of pregnancy, 407
Overall time, 457

P

Palladium-103, 1033
Palliative, 239
  Care cost, 203
  Radiation therapy, 223
Pancreatic
  Cancer, 305
  Carcinoma, 751
Parotid
  Gland, 1045
  Malignant tumors, 327
Pathological fractures, 217
Patterns
  Relapse, 261
  Recurrence, 321
Pd-103, 81
Periaortic lymph node irradiation, 501
Perioperative brachytherapy, 873
Permanent implants, 81
Personal computer, 633
pH dependence, 585
Pharmacokinetics, 593
Photons, 821
Pion, 573
Planning
  Radiation treatment, 419
  Radiotherapy, 99
  Three-dimensional treatment, 367, 781
  Treatment, 89, 169, 433
Plasmid DNA, 579
Plastic scintillator detectors, 1059
Pneumonitis, 977
  Interstitial, 401
Portal films, 621
Positive resection margin, 737
Postoperative
  Irradiation, 511
  Radiation, 605
  Radiotherapy, 737
Potentially lethal damage, 983
Prediction of radiation resistance, 63
Predictive assays, 339
Pregnancy, 407
Pre-incubation, 593
Premature chromosome condensation, 353
Preoperative radiation therapy, 387
Primary
  Non-Hodgkin's lymphoma of brain, 9
  Unknown, 743
Probability of normal tissue complication, 781
Prognostic
  Factors, 271, 907
  Variables, 327
Proliferation, 457
Prolongation, 457
Prostate
  Cancer, 141, 293
  Specific antigen, 47, 141
Protocol, 419
Proton therapy, 27
Pterygium, 533
Pulsed, 661
  Field gel electrophoresis, 353, 993

Q

Quality assurance, 621

R

Radiation, 3, 115, 305, 327, 333, 869, 941
  Beta, 533
  Complications, 19
  Dosage, 769
  Dosimetry, 433
  High LET (linear energy transfer), 573
  Induced second malignancies, 949
  Oncology, 633
  Postoperative, 605
  Prediction of resistance, 63
  Treatment planning, 419
Radiation therapy, 41, 47, 271, 443, 449, 519, 647, 715, 759, 853, 915, 949, 961, 1021, 1045
  Fractionated, 147
  Intraoperative, 751
  Palliative, 223
  Pre-operative, 387
Radical
  Prostatectomy, 141
  Treatment strategies, 239
Radiobiology, 81
Radioprotection, 333, 841
Radioprotectors, 579
Radiosensitivity, 69, 339, 345
  Intrinsic, 55
Radiosensitization, 983
  Halogenated pyrimidine, 353
Radiosensitizer(s), 353, 361
Radiosurgery, 19
  Stereotactic, 223
  Stereotaxic, 413
Radiotherapy, 127, 141, 217, 299, 313, 407, 413, 483, 491, 501, 525, 599, 615, 621, 639, 705, 725, 769, 863, 925, 1037
  Adjuvant, 907
  Charged particle, 881
  Fractionated, 803
  Helium ion, 881
  Intraluminal, 397
  Neon ion, 881
  Planning, 99
  Postoperative, 737
Rat rectum, 175
RBE, 573, 627
Reaction(s)
  Foot, 847
  Normal tissue, 393
Rectal
  Adenocarcinoma, 563
  Cancer, 387
  Injury, 175
Recurrence
  Breast, 941
  Local-regional, 285
  Patterns, 321
Recurrent lung cancer, 397
Regional hyperthermia, 759, 1003
Relative biological effectiveness, 821
Remote afterloading, 133
Repair
  Capacity, 69
  DNA, 983
Repopulation, 63, 847
Restriction enzymes, 993
Results, 715
  Treatment, 313
Reticulum cell carcinoma of brain, 9
Rib fracture, 949
RSU 1069, 551

S

SAR, 189
Scatter dose, 433
Sc 9L tumors, 831
Score functions, 419
SF_2, 55, 803
  In vitro, 63
Shielding, 175
16,16 dimethyl prostaglandin E2, 333
Skin, 361
  Neoplasms, 769
Small field versus large field technique, 183
Soft tissue
  Sarcoma, 615
  Tissue tumors, 69
Spinal cord, 539
  Compression, 217
Squamous cell carcinoma, 803
SR 4233, 551
Stem cells, 69
Stereotactic, 19
  External beam irradiation, 229
  Radiosurgery, 223
Stereotaxic radiosurgery, 413
Strontium-90, 533
Surgery, 313, 327, 1037
  Conservative, 925, 949
Survival
  Cell, 993
  Disease free, 653
  Long-term results, 261

T

TCD_{50}, 803
T-depletion, 401
TDF values, 281
Technique, 443
  Small field versus large field, 183
Temperature distribution, 1009
TGF, 573
Therapeutic radiology, 169
Therapy
  Combined modality, 781
  Intraoperative radiation, 751
  Preoperative radiation, 387
  Proton, 27
  Radiation, 41, 47, 271, 443, 449, 519, 647, 715, 759, 853, 915, 949, 961, 1021, 1045
  X-ray, 769
Thermal washout, 1003
^{31}P-NMR, 557
Three-dimensional (3-D)
  Computerized treatment planning, 153
  Treatment planning, 27, 367, 781
Thymoma, 1037
Time
  Doubling, 457
  Overall, 457
Tissue
  Inhomogeneity corrections, 433
  Necrosis, 949
Tolerance
  CNS, 27
  Normal tissue, 27
  Optic nerve, 27
T1, 299
Total body irradiation, 1051
  Hyperfractionated, 401
Transplant(s)
  Bone marrow, 1021
  HlA-matched bone-marrow, 401
Treatment
  Breast-conservation, 961
  Combined, 491
  Combined modality, 705
  Plan optimization, 153, 367
  Radical strategies, 239
  Results, 313
  Verification, 621
Treatment planning, 89, 169, 433
  Radiation, 419
  Three-dimensional (3-D), 27, 367, 781
  Three-dimentional computerized, 153
T2 bladder cancer, 299
Tubular carcinoma, 941
Tumor(s), 361
  Bile duct, 165
  Blood flow, 1003
  Human, 811
  Liver, 781
  Location, 933
  Malignant parotid, 327
  Registry, 633
  Sc 9L, 831
  Soft tissue, 69
Tumorectomy, 907
Two-dimensional modeling, 1009
^{241}Am, 175

U

Ultrasound, 165
Unknown primary, 743

V

Values
  ERD, 281
  TDF, 281
Vasodilator agents, 377
Verification
  Films, 621
  Treatment, 621
Vertex field, 429
Vitamin E, 841
Vocal cord cancer, 281
Volumetrics, 367

W

Wound complication, 41
WR-3689, 841

X

X-ray(s), 353
  Therapy, 769
Xenografts
  Human tumor, 803
  Melanoma, 63

Y

Young age group, 969